|
WO2018187158A1
|
|
Combination therapy of cancer with anti-endoglin antibodies and anti-programmed death receptor agents
|
|
US2018057602A1
|
|
Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
|
|
WO2018067819A1
|
|
Compositions and methods for treatment of cancers
|
|
US2016257755A1
|
|
Anti-endoglin antibodies and uses thereof
|
|
US2017335005A1
|
|
Anti-endoglin antibodies and uses thereof
|
|
SG11201501659SA
|
|
Antibody formulations and uses thereof
|
|
EP2558866A1
|
|
Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
|
|
AU2010300668A1
|
|
Endoglin antibodies
|
|
KR20150089096A
|
|
Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
|
|
TW201023883A
|
|
Humanized endoglin antibodies
|
|
CN104958299A
|
|
Antifolate agent combinations in the treatment of cancer
|
|
UA96614C2
|
|
Combinations of antifolate agent in the treatment of cancer
|
